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Background: Large differences exist in the prevalence rate of drugs prescribed to children and adolescents
between and within countries. The aim of this study was to evaluate child and adolescent drug prescription
patterns in Italy in an extra-hospital setting at the regional and Local Health Unit (LHU) levels.
Methods: Data sources were three regional prescription databases. Data concerning the year 2008 were evaluated.
A total of 3.3 million children and adolescents were included. Drug prevalence and prescription rates were
evaluated at the regional and LHU levels. The correlation between mean latitude, average annual income,
hospitalisation rate, number of paediatricians per 1,000 resident children, and prevalence rate was evaluated by LHU
using a linear multiple regression analysis.
Results: Large differences were found across Italian regions and LHUs. The mean prevalence rate was 56.4% (95%
CI 56.3-56.5%; 51.2-65.4% among regions) and, at the LHU level, ranged from 43.1% to 70.0% (higher in the South).
A total of 878 drugs were prescribed, 175 of which were shared by all LHUs. Amoxicillin clavulanate was the most
used drug in all regions and in 31 of 33 LHUs. Amoxicillin was the drug with the highest variability in use between
LHUs (9.1-52.1% of treated children). An inverse correlation was found between prevalence rate and both latitude
(p < 0.0001) and average annual income (p = 0.0002).
Conclusions: The use of drugs in children and adolescents is higher in southern Italy and is inversely related to
latitude and average annual income. More efforts should be devoted to informing physicians, patients and policy
makers in order to plan effective initiatives to improve the situation.
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Children are widely exposed to drugs, with an average
prevalence rate of 60% worldwide [1]. There is a large
variability between countries. Prevalence rates range
from 51% in Denmark to 70% in Greenland and pre-
scription rates range from 0.8 in Norway to 3.2 in the
United States [1]. The highest exposure is observed in
preschoolers (75-90%), while the prevalence rate de-
creases in children > 6 years old in all countries. The
peak prevalence rate varies from below 2 years old in the
United States to 3–5 years old in Greenland and Italy [1].
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reproduction in any medium, provided the orantibiotics (20–33% of total prescriptions), anti-asthmatics
(10-25%), and analgesics (10-16%) [1].
Quantitative and qualitative differences in antibiotic
exposure between countries are well documented. For
example, an Italian child has, on average, a fourfold
higher risk of being exposed to antibacterial drugs than
an English child and a threefold higher risk than a Dutch
child [2]. Cephalosporins, a second line treatment in most
paediatric infections, are widely prescribed in Italy (39% of
paediatric antibiotic prescriptions) while in the Netherlands
and Denmark this class represents less than one percent of
total antibiotic paediatric prescriptions [2].
There is heterogeneity also in children’s exposure to
respiratory system drugs between different countries:
prevalence rates range from 6.2% in Norway to 19% in
Italy [3]. ß2-mimetics and inhaled steroids are the mostLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the use of inhaled steroids is threefold and fourfold
higher than in UK and in the Netherlands, respectively
[4].
Wide international variation exists also in the preva-
lence rates of other, less common, classes of drugs used
for chronic treatment in children, such as anti-epileptic
and anti-diabetic drugs [5,6]. Such heterogeneity in dif-
ferent parts of the world may reflect differences both in
prescription habits and in prevalence of diseases.
Prescribing differences exist also within Italy: the over-
all prevalence rate for all prescribed drugs in children is
57.3% in the North and 68.3% in the South [7]. Notable
differences have been reported also within regions. This
is the case of the Lombardy region, where, in 2006,
prevalence rates for all drugs ranged from 38.4% in
Milan’s local health unit (LHU) to 54.8% in Brescia’s [8].
The literature suggests that the geographic factor is
one of the most important determinants in drug pre-
scription. In this context, a comparison between pre-
scribing profiles at the LHU level was made, involving
three prominent Italian regions: Lombardy, Lazio, and
Puglia. The main goal of this study was to evaluate the
influence of territorial setting on the drug prescription
profile of a child and adolescent outpatient Italian popu-
lation. The association between prevalence rates and a
few socio-economic determinants was investigated.
Methods
The Italian national health service (NHS)
Italian healthcare is provided free or at a nominal charge
through a network of LHUs. Every Italian resident is reg-
istered with a family (paediatric or general) practitioner.
Children are assigned to a paediatrician until they are 6 -
years old; afterwards, the parents can choose to register
a child with a general practitioner. All adolescents > 13 -
years old are assigned to a general practitioner. A
national formulary is available, in which drugs are
categorised into two classes: class A includes essential
drugs that patients do not have to pay for and class C
contains drugs not covered by the NHS (e.g. contracep-
tives, nonsteroidal anti-inflammatory drugs, dermato-
logic drugs).
Data source
The data sources were regional databases routinely
updated for administrative and reimbursement reasons.
The databases stored all community (i.e. outside hos-
pital) prescriptions reimbursed by the NHS. Aggregated
and anonymous data were provided by the regional
health ministry of Lombardy, Lazio and Puglia regions.
No approval by an ethic committee was required. The
study population was composed of 3,301,096 children
and adolescents < 18 years old. It represented about onethird of the population for that age group, living in three
large Italian regions: Lombardy (1,616,268 resident chil-
dren, North Italy), Lazio (926,015 children, Centre), and
Puglia (758,813 children, South).
All drugs were classified according to the ATC system
(Anatomical Therapeutic Chemical classification system).
The observation period was from 1 January to 31 Decem-
ber 2008. A total of 33 LHUs were included in the study.
Measures
The following measures were used in order to describe
the prescription profile:
1) prevalence rate, expressed as the percentage of
resident children/adolescents (<18 years old)
receiving at least one prescription in one year.
2) prescription rate, expressed as number of
prescriptions per treated children (every child/
adolescent receiving at least one prescription in one
year was considered a treated child). These measures
were retrieved at the regional and LHU levels.
The percentage of treated children for the 10 most
prescribed active substances was calculated at the re-
gional and LHU levels.
The all-cause hospitalisation rate was calculated for
each LHU, expressed as number of children with at least
one hospital admission in one year divided by 1000 resi-
dent children/adolescents. The number of paediatricians
per 1000 resident children was calculated for each LHU.
The number of active substances used at least once
across the three regions and across LHUs were retrieved
(shared drugs). The drugs shared by all LHUs of each re-
gion were compared with the WHO “List of essential
medicines for children” [9], and with the British National
Formulary for children (BNF for children) year 2011.
The ranks corresponding to the percentage of treated
children for the 10 most prescribed active substances
were compared by using the W Kendall concordance
test (regional level).
The non-parametric Spearman test was used to evalu-
ate the correlation between prevalence rates and the fol-
lowing determinants at the LHU level:
– latitude,
– hospitalisation rate for all causes,
– number of paediatricians per 1000 resident children,
– average annual income.
A stepwise linear multiple regression analysis was
performed considering each LHU’s prevalence rate as
the dependent variable group and the aforementioned
four determinants as the independent variable groups
(fixing α = 0.15).
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ratio of the standard deviation (SD) to the mean for
various measures. The Mantel-Haentzel χ2 test was
performed in order to compare the drug prescription
prevalence in boys and girls. A choropleth map of avail-
able prevalence rate data for LHUs was created using
the software Arcmap version 10. The prevalence values
were categorised into three classes calculated on the basis
of the mean ± SD. Statistical analysis was performed using
SAS software, version 9.1.Results
Prescription profile
During 2008, 1,861,425 children and adolescents (56.4%
of the study population, 95% CI 56.3-56.5%) received at
least one drug prescription. Prevalence and prescription
rates by region are reported in Table 1. The prevalence
rate of all drugs was slightly higher in boys than in girls
for all ages (57.3 vs 55.4%; χ2 = 1261; p < 0.001). The
male/female odds ratio for prevalence rate for all drugs
was, on average, 1.08, with no statistically significant dif-
ferences found between the three regions. The trend for
gender was similar up to 15 years of age, after which the
prevalence rate for girls was higher than that for boys.
The profile curve of the prevalence rate by age was very
similar in the three regions (Figure 1).
A total of 6,844,307 prescriptions were dispensed.
Each treated child/adolescent received 3.7 ± 0.4 prescrip-
tions. Boys received more prescriptions (3.8 vs. 3.5) than
girls. Infants (<6 years old) treated with at least one drug
received more prescriptions (4.3 prescriptions per
treated individual) than children (3.3) and adolescents
(3.1). The highest number of prescriptions/treated child
was observed in 4 year old children (4.7).Prescription profile by LHU
The prevalence rate for all drugs among all LHUs ranged
from 43.1% to 70.0%, with a CV = 0.12 (Figure 2). The
within-region CV among the different LHUs ranged
from 0.04 in Puglia to 0.09 in Lazio.
The prescription rate ranged from 2.9 to 4.8 with a
CV = 0.12. The within-region CV among the different
LHUs ranged from 0.05 in the Lombardy Region to 0.09
in the Lazio Region.Table 1 Prevalence (%) and prescription rates (number of
prescriptions/treated children) by regions
Prevalence rate Prescription rate
Lombardy 51.2 (43.1-56.3) 3.3 (2.9-3.6)
Lazio 58.1 (49.9-68.1) 3.8 (3.4-4.4)
Puglia 65.4 (62.5-70.0) 4.2 (3.9-4.8)
Ranges by local health unit (LHU) are reported in brackets.Determinants of prescriptions
Spearman’s tests found an inverse correlation between
prevalence rate and latitude (rS = −0.78; p < 0.0001) and
between prevalence rate and average annual income (rS =
−0.81; p < 0.0001). Hospitalisation rate showed a weak cor-
relation with prevalence rate (rS = 0.49; p = 0.005).
The multiple linear regression model confirmed the
inverse association of prevalence rates toward latitude
(partial R-squared = 0.76; p < 0.0001) and average annual
income (partial R-squared = 0.10; p = 0.0002), while the
hospitalisation rate and number of paediatrician per
1000 resident children did not reach the minimum sig-
nificance value.
Active substances
A total of 878 different active substances were pre-
scribed, ranging from 639 in Puglia to 800 in Lombardy.
Of these active substances, 530 were shared by the three
regions, and 175 by all the LHUs. The number of active
substances shared by all the LHUs of a single region
ranged from 190 in the Lombardy region to 340 in the
Puglia region.
The drugs shared by all the LHUs belonged to 45
therapeutic main groups. The most represented were:
antibacterials for systemic use (J01), with 35 active sub-
stances; and drugs for obstructive airway diseases (R03),
with 13 active substances. Among the 35 antibiotics, the
most represented classes were cephalosporins (9 active
substances), and macrolides (8).
Of the drugs shared by all LHUs, 139 out of 175 (79%)
were included in the BNF for children and 46 out of 175
(26%) were included in the WHO “List of essential med-
icines for children”. Of the 36 drugs prescribed in all the
LHUs, but not included in the BNF for children, 12 were
antibiotics. The 10 most prescribed active substances at
the regional level comprised, on average, 65.5% of all pre-
scriptions (from 62.4% in Puglia to 68.5% in Lombardy).
The W Kendall test scored a concordance coefficient of
0.81 (p < 0.01). Ranks associated with each active sub-
stance are reported for each region in Table 2. Of the
10 most prescribed active substances, only 6 were in
the top 10 in all the LHUs. Of these, the drug with the
most heterogeneous prevalence rate was amoxicillin,
with a rate ranging from 9.1% to 52.1% of treated children
among all LHUs (CV = 0.47). The drug with the most
homogeneous prevalence rate was amoxicillin clavulanate
(CV = 0.10), covering 41.6% (33.8-52.1%) of treated chil-
dren. Beclometasone was the most used respiratory-
system drug and scored second in rank among all active
substances, with 23.5% (12.5-30.2%) of treated children.
Amoxicillin was the second most prescribed drug in the
Lombardy region, while it was the sixth and seventh in
the Puglia and Lazio regions. Ranks associated with the
most prescribed drugs were not statistically different
Figure 1 Prevalence rate by age. All drugs prevalence rate (%) by age (year) for each region.
Figure 2 Prevalence rate of drugs. Choropleth map of regions and Local Health Units (LHUs) included in the study. The prevalence values
were categorised into three classes calculated on the basis of the mean ± SD.
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Table 2 List of the most 10 most used active substances
in the population study and in the three regions ordered
by % of treated children





amoxicillin clavulanate 41.6 43.2 (1) 40.2 (1) 41.5 (1)
beclometasone 23.5 18.8 (3) 26.2 (2) 25.5 (2)
clarithromycin 18.5 14.3 (5) 18.8 (3) 22.5 (3)
amoxicillin 18.2 27.7 (2) 13.3 (7) 13.7 (6)
salbutamol 14.8 15.2 (4) 17.9 (4) 11.2 (7)
cefixime 13.8 6.6 (9) 15.7 (5) 19.2 (4)
azithromycin 12.8 10.4 (6) 12.8 (8) 15.2 (5)
betametasone 9.7 7.2 (8) 13.6 (6) 8.3 (9)
cefaclor 8.0 7.5 (7) 9.2 (9) 7.2 (11)
cetirizine 5.9 5.8 (10) 6.6 (11) 5.4 (15)
0-5 years old Lombardy Lazio Puglia
amoxicillin clavulanate 48.6 49.5 (1) 46.1 (1) 49.9 (1)
beclometasone 31.5 25.9 (3) 36.4 (2) 36.7 (2)
amoxicillin 27.5 37.0 (2) 19.4 (5) 18.4 (5)
salbutamol 22.4 21.6 (4) 27.1 (3) 18.1 (6)
clarithromycin 20.9 14.6 (5) 23.6 (4) 30.1 (3)
cefixime 13.5 6.7 (11) 18.4 (7) 21.2 (4)
betametasone 13.5 11.8 (6) 18.6 (6) 10.8 (12)
azithromycin 12.8 9.8 (8) 13.6 (8) 17.9 (7)
cefaclor 11.7 11.5 (7) 12.7 (9) 11.0 (10)
flunisolide 7.9 7.7 (9) 7.8 (11) 8.9 (14)
6-11 years old Lombardy Lazio Puglia
amoxicillin clavulanate 41.7 42.6 (1) 40.9 (1) 41.1 (1)
beclometasone 19.8 15.8 (3) 22.8 (2) 23.0 (2)
clarithromycin 16.2 14.2 (4) 17.0 (3) 18.7 (4)
amoxicillin 16.2 23.3 (2) 9.9 (9) 11.3 (6)
cefixime 12.8 6.6 (8) 15.5 (4) 19.8 (3)
azithromycin 12.7 10.8 (6) 12.8 (6) 15.5 (5)
salbutamol 12.5 12.5 (5) 15.4 (5) 9.4 (7)
betametasone 8.1 5.3 (10) 11.7 (7) 8.6 (8)
cefaclor 7.8 6.6 (9) 10.0 (8) 7.6 (10)
cetirizine 7.5 7.7 (7) 8.1 (10) 6.8 (12)
12-17 years old Lombardy Lazio Puglia
amoxicillin clavulanate 31.9 33.2 (1) 30.5 (1) 31.5 (1)
clarithromycin 14.8 13.7 (3) 13.8 (3) 17.5 (2)
beclometasone 12.8 10.2 (5) 15.0 (2) 14.4 (4)
amoxicillin 12.6 17.2 (2) 8.2 (7) 10.5 (6)
azithromycin 11.3 11.0 (4) 11.7 (5) 11.4 (5)
cefixime 10.9 6.4 (8) 12.0 (4) 16.0 (3)
salbutamol 6.5 7.5 (6) 7.3 (8) 4.5 (9)
cetirizine 5.6 6.5 (7) 5.3 (9) 4.7 (8)
Table 2 List of the most 10 most used active substances
in the population study and in the three regions ordered
by % of treated children (Continued)
betametasone 4.7 1.8 (15) 8.3 (6) 5.1 (7)
levocetirizine 4.6 4.5 (9) 5.0 (10) 4.3 (10)
The numbers in brackets represent the rank corresponding to each active
substance in each region.
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adolescents).Discussion
This study provides an analysis of the prevalence of drug
use in children and adolescents in three large Italian re-
gions with different socio-economical and geographical
characteristics. About one third of the child/adolescent
Italian population was included.
The prevalence was heterogeneous across the different
regions and even more so across LHUs. The Lazio re-
gion had the highest within-region variability, while the
Lombardy and Puglia regions had, respectively, the low-
est and the highest prevalence rates. The linear regres-
sion model found a strong inverse correlation between
prevalence rates and latitude, and between prevalence and
average annual income. The average annual income (per-
capita) in southern areas of Italy is lower than in northern
ones (19,541 € in Puglia vs 25,488 € in Lombardy) and
drug use in children and adolescents is higher in these re-
gions and LHUs. Some evidence of similar findings is
available from other studies, [10,11] but these were not
related to outpatient children and adolescents. The regres-
sion model did not find relevant correlation between
prevalence rates and hospitalisations for all causes (as
moderate/severe “proxy of disease”) indicating that an in-
creased use of drugs in children, in general, is not closely
related with a higher disease prevalence.
There are other factors which we could not investigate
in our study such as the paediatricians attitude to pre-
scription and the perceived parental expectation of a
prescription which are two important factors influencing
ambulatory antibiotic prescriptions to children in Italy
[12,13]. Other studies found that both low educational
and socioeconomic status of parents were associated
with a higher risk of non-adherence to physician indica-
tions in antibiotic use [14,15] causing a higher rate of
treatment failure and thus the need of a new prescrip-
tion. Out of pocket drug prescriptions, which are not de-
tectable in our database, has been associated to a higher
socioeconomic and educational status of patients [14],
however the phenomena is probably limited for out-
patient children and adolescents.
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It is interesting to note that 40% of the 878 drugs pre-
scribed was not shared at the regional level, and that
only 20% was used at least once in all 33 LHUs. The list
of drugs shared by all the LHUs (175 drugs) could be
considered “essential”, independently of geographical
setting. Nevertheless, redundancies also exist within this
list. This is particularly evident when antibiotics, a class
that covered 21% of the list, are considered. A low over-
lap (26%) between this list of drugs and the WHO “List
of essential medicines for children” is in part expected,
since this latter represents a minimal list of medicinal
for priority conditions and for a basic health care system.
It is notable, however, that three quarters of these shared
drugs are not considered “essential” from a public health
point of view. In all, 20% of the shared drugs were not
reported in the BNF for children, despite the fact that
the BNF is considered a reference formulary at the inter-
national level. In order to promote a more homogeneous
and rational use of drugs in children at the national level,
the adoption of a common, acknowledged European for-
mulary of paediatric medicines should be considered [16].
The most widely used drug was amoxicillin clavulanate.
Most Italian paediatricians still consider it as the first choice
drug for paediatric infectious diseases, as already docu-
mented in the 0–14 year old Italian population [17]. Des-
pite the fact that amoxicillin clavulanate has a wider activity
spectrum than amoxicillin alone, toxicity is higher and the
cost effectiveness (for infections caused by non-β-lactamase
producing bacteria) is lower [18,19].
Amoxicillin was the active substance with the highest
variability in use between the different LHUs: there was al-
most a six fold higher consumption between LHUs ranked
as the first and the last. Amoxicillin should be the most
widely used drug. National and international guidelines
consider it the first line treatment for acute respiratory in-
fections (in particular pharyngotonsillitis and acute otitis
media) [20-28], which are the most prevalent diseases in
children. It is a major concern that in Lazio and Puglia
amoxicillin was, respectively, the seventh and the sixth
most used drug. In Lazio school-aged children amoxicillin
was only the ninth most used drug. No data on paediatric
resistance in outpatients are available at the regional level,
but it is unlikely, although possible, that an increased
prevalence of β-lactamase producing bacteria in the South
could be responsible for such macroscopic differences. In
the LHU with the highest consumption of amoxicillin
(Lombardy Region), a training program for paediatricians,
based on the main international guidelines on paediatric
infectious diseases, [29] has been running since 2004. The
data from the current study confirms that such interven-
tions can have a large impact on prescription habits.
Beclometasone was the second most prescribed drug
in the study population. In Italy beclometasone isprescribed mainly as symptomatic treatment of upper
respiratory tract infections and is quite never prescribed
for asthma therapy [30,31]. Beclometasone was more
prescribed in the South, suggesting that contexts with a
higher prevalence of drug prescriptions are characterised
by greater inappropriateness.
Overall findings suggest that reported national drug pre-
scription rates should be viewed with criticism if within
country differences are not considered or reported.
Strengths and limits
To date this is the largest study looking at drug prescrip-
tions in Italian children and adolescents.
The observed prevalence rate was similar compared to
what documented in a previous study including 22
Italian LHUs [7]. In comparison with the previous study
we were able to include all the LHUs of three large regions
representative of different economic, socio-demographic,
and geographic settings, allowing the comparison of the
different regional prescription profiles. The current study
also included the analysis of other determinants of pre-
scriptions and the analysis of the number of active sub-
stances shared by regions and LHUs.
Nevertheless, there are some limitations. Information
on the disease was lacking, but this is an intrinsic limita-
tion of all pharmacoepidemiology studies using pre-
scription databases. Data concerning the use of private
paediatric practice across the three regions was not
available. Differences in the use of private practice could
potentially influence the different prescription patterns
observed in our study since only reimbursed prescrip-
tions are detectable in our database. Other data, how-
ever, suggest that the out-of pocket drug use may be
limited for reimbursed drugs [32].
We did not include data from a random sample of the
Italian population (because such data were not available
for all regions/LHUs), thus, from a strictly statistical
point of view, our results may not be valid for all Italian
regions. However, we included three large regions (from
North, Centre, and South of Italy, which represent al-
most 1/3 of the Italian child population) which are quite
representative of the differences in socio-economic status
found in Italy. Moreover, the fact that drug consumption
is higher in southern Italy is reported in the annual report
conducted by OsMed [33] (Osservatorio sull’impiego dei
medicinali) in the general population, thus it is very likely
that this trend is maintained in children.
Conclusions
In conclusion, this is the first study that compares the
complete drug prescription profile in outpatient children
of three of the most prominent Italian regions.
The data indicates that Italian prevalence rate of drugs
in children and adolescents is similar to that observed in
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lence rate in southern Italy. The average annual income
was inversely related to drug prescriptions, recalling a
well-known North–South gap. Focused studies are
warranted to clarify the role of other determinants or
possible confounders such as socio-cultural factors, phy-
sicians prescribing attitude, the use of private practice,
out-of-pocket drug use, marketing strategies and medi-
cation adherence across the different areas. More efforts
should be devoted to informing physicians and patients,
as well as policy makers, of such a scantly rational use of
drugs in Italian children while waiting for effective initia-
tives aimed at improving the situation.
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